{"product_id":"contrast-media-agent-and-injector-system-market-a-global-and-regional-analysis-focus-on-product-and-country-analysis-analysis-and-forecast-2022-2026","title":"Contrast Media Agent and Injector System Market - A Global and Regional Analysis: Focus on Product and Country Analysis - Analysis and Forecast, 2022-2026","description":"\u003cp\u003eContrast Media Agent and Injector System Market - A Global and Regional Analysis: Focus on Product and Country Analysis - Analysis and Forecast, 2022-2026\u003cbr\u003e\nGlobal Contrast Media Agent and Injector System Market Industry Overview\u003c\/p\u003e\n\n\u003cp\u003eThe global contrast media agent and injector system market was valued at $7,634.6 million in 2022 and is expected to reach $9,712.3 million by 2026, growing at a CAGR of 6.20% during the forecast period 2022-2026. The market is driven by factors such as the increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector system and image-guided diagnostics.\u003c\/p\u003e\n\n\u003cp\u003eMarket Lifecycle Stage\u003c\/p\u003e\n\n\u003cp\u003eThe global contrast media agent and injector system market is developing. The global contrast media agent and injector system market has witnessed several collaborations among the market players. The collaborations are aimed at combining capabilities, expanding the customer base, and marketing, among others.\u003c\/p\u003e\n\n\u003cp\u003eThe opportunity for growth of the global contrast media agent and injector system market lies in continued research and development activities for manufacturing innovative contrast media agent and injector system. Many pharmaceutical companies are expanding their businesses and becoming more outsourcing-oriented.\u003c\/p\u003e\n\n\u003cp\u003eImpact of COVID-19\u003c\/p\u003e\n\n\u003cp\u003eThe COVID-19 pandemic has significantly impacted the world's healthcare sector, especially the contrast media agent and injector system sector. The COVID-19 pandemic led to the rescheduling of non-essential diagnostic tests and treatment procedures in order to allocate more resources toward the management of COVID-19. The American College of Radiology postponed non-urgent outpatient visits in accordance with the guidelines put forth by the Centers for Disease Control and Preventio (CDC). According to a paper published in the Radiological Society of North America (RSNA) in April 2020, titled ‘The Economic Impact of the COVID-19 Pandemic on Radiology Practices,’ imaging volumes were affected with the greatest decline observed in outpatient settings, followed by emergency departments and inpatient settings.\u003c\/p\u003e\n\n\u003cp\u003eThe future impact of COVID-19 on the demand and supply across the global contrast media agent and injector system market depends on the abilities of stakeholders to withstand unforeseeable scenarios in the future. The intensity of impact due to COVID-19 in the future will depend on the current efforts being made by companies to equip their supply chains with the necessary components and processes to remain responsive.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation 1: by ProductContrast Media AgentsInjector SystemsThe global contrast media agent and injector system market (by product) is expected to be dominated by the contrast media agents segment.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation: Contrast Media Agents (by Modality)X-Ray\/CT ScanMRIUltrasoundThe global contrast media agent market (by modality) is expected to be dominated by the X-Ray\/CT scan.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation: Contrast Media Agents (by Type of Media Agent)Iodine-Based Contrast Media AgentGadolinium-Based Contrast Media AgentBarium-Based Contrast Media AgentMicrobubble Contrast Media AgentOthersThe global contrast media agent market (by type of media agent) is expected to be dominated by iodine-based contrast media agent.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation: Injector Systems (by Modality)CT Injector SystemsMRI Injector SystemsCardiovascular\/Angiography Injector SystemsThe global contrast media injector system market (by modality) is expected to be dominated by CT injector systems.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation: Injector Systems (by Product)InjectorConsumables and AccessoriesThe global contrast media injector system market (by product) is expected to be dominated by consumables and accessories.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation: Injector Systems (by Injector Type)Single-Head InjectorsDual-Head InjectorsSyringeless InjectorsThe global contrast media injector system market (by injector type) is expected to be dominated by single-head injectors.\u003c\/p\u003e\n\n\u003cp\u003eSegmentation 2: by RegionNorth America -    U.S., CanadaEurope - Germany, U.K., France, Italy, Spain, and Rest-of-EuropeAsia-Pacific - China, Japan, India, Australia, and Rest-of-Asia-PacificRest-of-the-WorldThe global contrast media agent and injector system market (by region) is dominated by the North America region.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in Global Contrast Media Agent and Injector System MarketIn January 2023, Bayer AG received approval in Europe for its Ultravist-300, -370, an iodine-based contrast agent for contrast-enhanced mammography (CEM).In December 2022, Beijing Beilu Pharmaceutical Co. Ltd. expanded its business by establishing a wholly-owned subsidiary in Hong Kong.In April 2022, Beijing Beilu Pharmaceutical Co., Ltd.’s gadobutrol injection received the Drug Registration Certificate from the National Medial Production Administration (NMPA).In February 2023, Bracco Group partnered with Wellstar Health System. Through this partnership, the company conducted trials for its FDA-approved VUEWAY (gadopiclenol) injection, which is a contrast agent for use in MRI.In February 2023, Bracco Group acquired all the shares of Bracco-Eisai from Eisai. Furthermore, the company also changed the name of the company from Bracco-Eisai to Bracco Japan, Ltd.In July 2022, Fresenius Kabi, a subsidiary of Fresenius SE \u0026amp; Co. KGaA, launched its range of generic contrast media agents’ generics in the U.S.In December 2022, General Electric Company partnered with ulrich GmbH \u0026amp; Co. KG. Through this partnership, the companies aimed to offer a branded multi-dose contrast media injector in the U.S.Demand - Drivers and Limitations\u003c\/p\u003e\n\n\u003cp\u003eThe following are the drivers for the global contrast media agent and injector system market:Increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector systemUpsurge in demand for image-guided diagnosticsGrowing number of regulatory approvalsThe market is expected to face some limitations as well due to the following challenges:Rising health concerns post usage of contrast media agents in the bodyHow can this report add value to an organization?\u003c\/p\u003e\n\n\u003cp\u003eGrowth\/Marketing Strategy: The global contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Strategy: The global contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies have the opportunity to expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals.\u003c\/p\u003e\n\n\u003cp\u003eKey Companies ProfiledBayer AGBeijing Beilu Pharmaceutical Co. Ltd.Bracco GroupFresenius SE \u0026amp; Co. KGaAFUJIFILM Holdings CorporationGeneral Electric CompanyGuerbetJiangsu Hengrui Pharmaceutical Co., Ltd.Jodas Expoim Pvt. Ltd.Lantheus Holdings, Inc.Shenzen Seacrown Electromechanical Co., Ltd.Sino Medical-Device Technology Co., Ltd.ulrich GmbH \u0026amp; Co. KGUnijules Life Sciences Ltd.\u003c\/p\u003e\n\n\u003cp\u003e*PDF email from publisher allows for 1-3 users, with permission to print*\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 183 Pages \/ MCW16237091","offer_id":47652360519986,"sku":null,"price":6600.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/contrast-media-agent-and-injector-system-market-a-global-and-regional-analysis-focus-on-product-and-country-analysis-analysis-and-forecast-2022-2026","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}